DANAHER CORPORATION

(DHR)
  Report
Delayed Nyse  -  05/18 04:04:25 pm EDT
243.60 USD   -2.16%
05/12DANAHER CORP /DE/ : Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
AQ
05/12Danaher Ratifies the Selection of Ernst & Young LLP as the Company's Independent Registered Public Accounting Firm for the Year Ending December 31, 2022
CI
05/12Danaher Joins Bespoke Gene Therapy Consortium (BGTC) for Rare Diseases
PR
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Evolution of the average Target Price on DANAHER CORPORATION
Target Price consensus revisions : last 18 months
Recommendations (Chart) DANAHER CORPORATION
Analyst Recommendations on DANAHER CORPORATION
04/25UBS Adjusts Danaher Price Target to $340 From $365, Maintains Buy Rating
MT
04/25Wells Fargo Downgrades Danaher to Equalweight from Overweight, Adjusts Price Target to $26..
MT
04/22RBC Cuts Price Target on Danaher to $299 From $311, Maintains Sector Perform Rating
MT
04/13RBC Raises Price Target on Danaher to $311 From $276, Maintains Sector Perform Rating
MT
04/07ANALYST RECOMMENDATIONS : Abbvie, Aerojet, Blackstone, Bristol-Myers Squibb, Ford...
04/04Evercore ISI Adjusts Price Target for Danaher to $325 From $330, Maintains Outperform Rati..
MT
03/15RBC Cuts Price Target on Danaher to $276 From $302, Maintains Sector Perform Rating
MT
More recommendations
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 21
Last Close Price 243,60 $
Average target price 324,00 $
Spread / Average Target 33,0%
High Price Target 375,00 $
Spread / Highest target 53,9%
Low Price Target 200,00 $
Spread / Lowest Target -17,9%
Consensus detail
Consensus revision (last 18 months)